CalciMedica, Inc. Annual Report - A Closer Look

Unlock the insights into CalciMedica, Inc.'s financial health and strategic direction. This summary provides an investor-focused overview of the company's performance and outlook, drawn directly from its annual report for the fiscal year ended December 31, 2025. We've translated key aspects of their business, financial standing, and future prospects into plain language.

Business Overview

CalciMedica, Inc. is a clinical-stage biopharmaceutical company that discovers and develops new treatments for inflammatory and autoimmune diseases. Its lead product candidate, Auxora, is a small molecule designed to block calcium channels (CRAC channels) that play a role in inflammation. The company is developing Auxora to treat acute pancreatitis and other severe inflammatory conditions. As a company without approved products generating revenue, CalciMedica's main focus and measure of progress are advancing its clinical programs and developing its pipeline.

Financial Performance - Revenue, Profit, and Expenses

As a clinical-stage company without approved products, CalciMedica did not generate significant product revenue in fiscal year 2025. The company reported a substantial net loss, primarily due to its intensive research and development (R&D) activities and general administrative expenses.

• Revenue: Consistent with its clinical-stage status, CalciMedica generated no significant product revenue in fiscal year 2025, unchanged from 2024.
• Net Loss: CalciMedica reported a net loss for fiscal year 2025. This loss, reflecting the high costs of drug development, increased from 2024, mainly due to higher R&D spending as clinical trials advanced.
• Research & Development (R&D) Expenses: R&D remained the largest expense in 2025. This increased from 2024 as the company funded ongoing Auxora clinical trials and preclinical development for other candidates.
• General & Administrative (G&A) Expenses: G&A expenses were up from 2024, supporting corporate functions and public company operations.

These figures highlight the capital-intensive nature of biotech, where substantial investment is required before potential commercialization.

Management's Discussion and Analysis (MD&A) Highlights

Fiscal year 2025 saw significant investment in research and development (R&D) as CalciMedica advanced its clinical programs. Management's strategic focus remained on progressing Auxora through clinical development and carefully managing capital resources.

Key Achievements:

• Clinical Progress for Auxora: CalciMedica successfully completed patient enrollment for its clinical trial of Auxora in acute pancreatitis. Top-line data is expected in early 2026. This milestone significantly drove increased R&D expenses.
• Pipeline Expansion: The company initiated preclinical studies for a new candidate targeting autoimmune diseases, broadening its therapeutic focus and adding to R&D costs.
• Strategic Financing: CalciMedica successfully raised through a public stock offering. This strengthened its balance sheet, extended its operational runway, and was critical for supporting increased R&D activities.

Significant Challenges:

• Increased R&D Costs: The complexity and duration of clinical trials led to higher-than-anticipated R&D spending, contributing to the increased net loss.
• Regulatory Delays: The company experienced minor delays in securing regulatory approvals for certain clinical trial sites. While this slightly impacted timelines, it did not materially affect the lead program's overall progress.
• Competitive Landscape: CalciMedica navigates an increasingly competitive environment. Other companies pursue treatments for similar indications, requiring continuous innovation and strategic positioning.

Management believes increased R&D investment is necessary to achieve critical clinical milestones and advance product candidates, essential for long-term value. The successful financing round was key to mitigating the financial impact of these increased costs and ensuring continued operational capacity.

Financial Health - Debt, Market Value, and Future Funding

For a clinical-stage biotech, CalciMedica's financial health is crucial to sustain its long development cycles.

• Debt: The company reported no significant long-term debt as of December 31, 2025.
• Market Value: The public market value of its common stock was approximately $15.7 million as of June 30, 2025.
• Shares Outstanding: Approximately 15.7 million shares of common stock were outstanding as of February 25, 2026.
• Future Funding Needs: The company explicitly states it will require additional capital to complete Auxora's development and commercialization, as well as other product candidates. This future funding may come from equity offerings, debt financing, or strategic partnerships, each with potential implications for existing shareholders.

Key Risks That Could Impact the Stock Price

Investing in a clinical-stage biotech company like CalciMedica involves significant risks:

• Clinical Trial Success: The primary risk is uncertain clinical trial outcomes. Auxora or other candidates may fail to demonstrate efficacy or safety, or trials may face delays or termination.
• Regulatory Approval: Even with positive trial data, regulatory approval is not guaranteed. Delays or rejections would severely impact the company.
• Funding Risk: The company's ability to raise additional capital on favorable terms is crucial. Failure to secure funding could delay or curtail operations, or even halt development programs.
• Intellectual Property: Protecting its patents and proprietary technology is vital. Challenges to its intellectual property could undermine its market position.
• Competition: The therapeutic areas CalciMedica targets are highly competitive. Other companies may develop superior or more cost-effective treatments.
• Economic and Global Factors: Broader economic downturns, rising interest rates, inflation, or geopolitical events can impact funding, operational costs, and clinical trial execution.
• Nasdaq Listing Compliance: The company must continuously meet Nasdaq Capital Market listing requirements to maintain its public trading status.

Competitive Positioning

CalciMedica operates in highly competitive therapeutic markets. Its competitive strategy focuses on Auxora's unique way of working, by targeting CRAC channels, which could offer a distinct approach to treating inflammatory diseases. The company believes Auxora's potential to address unmet medical needs in conditions like acute pancreatitis could provide a competitive advantage. However, it faces competition from established pharmaceutical companies and other biotech firms developing treatments for similar indications, some with greater financial resources and more advanced pipelines.

Leadership and Strategy

CalciMedica's leadership team remained stable during 2025, focusing on executing its core strategy:

• Advancing Auxora: Prioritizing Auxora's clinical development and regulatory pathway in acute pancreatitis, and exploring additional indications.
• Pipeline Development: Prudently investing in preclinical research to expand its pipeline beyond Auxora.
• Strategic Partnerships: Actively evaluating potential collaborations or partnerships to accelerate development and commercialization.
• Talent Acquisition: Emphasizing attracting and retaining key scientific, medical, and management talent, critical for a development-stage company.

Future Outlook

CalciMedica's future success hinges on the successful clinical development, regulatory approval, and eventual commercialization of Auxora and its other product candidates. Key upcoming milestones include:

• Report top-line data from the trial of Auxora in acute pancreatitis in 2026.
• Initiate a pivotal trial for Auxora, pending positive data and regulatory feedback.
• Continue preclinical development for its earlier-stage programs.
• Secure additional funding to support long-term development plans.

The company remains focused on addressing significant unmet medical needs through innovative science, carefully managing financial resources, and navigating the complex regulatory landscape.

Market Trends and Regulatory Changes

CalciMedica acknowledges that broader market trends and regulatory shifts significantly influence its operations and financial performance. This includes:

• Legislative and Regulatory Changes: Potential changes in healthcare laws, drug pricing regulations, and approval processes in the U.S. and internationally could impact CalciMedica's business model and profitability.
• Economic Uncertainty: Global economic uncertainty, including rising interest rates, inflation, and geopolitical conflicts, can affect CalciMedica's ability to raise capital, conduct clinical trials, and manage operational costs.
• Public Health Crises: Future pandemics or public health emergencies could disrupt clinical trials, supply chains, and overall business operations.